KIFC2

Across TCGA pan-cancer cohorts, KIFC2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KIFC2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher KIFC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIFC2 expression acts as an unfavorable survival marker.

COAD, UCEC, and ACC are the cancer types where KIFC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.146	0.564	.021	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	OS	Median	IV	0.183	0.598	.036	3	view →
LUSC	DFS	Median	II,III,IV	0.280	0.600	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KIFC2–COAD (DFS)

Open the COAD breakdown →